Fairmount Funds Management LLC

Insider Reports History

Entity
Company
Location
200 Barr Harbor Drive, Suite 400, West Conshohocken, PA
Signature
/s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Fairmount Funds Management LLC:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Apogee Therapeutics, Inc. Director Common Stock 2.05M $76.3M $37.26 Mar 28, 2024 By Fairmount Healthcare Fund II LP
Viridian Therapeutics, Inc.\DE Director, 10%+ Owner Common Stock 3.45M $64.6M $18.75 Sep 13, 2024 Fairmount Healthcare Fund II LP
Oruka Therapeutics, Inc. Director, 10%+ Owner Common Stock 2.57M $59.2M $23.00 Sep 11, 2024 By Fairmount Healthcare Co-Invest III L.P.
Cogent Biosciences, Inc. Director Common Stock 6.23M $46.7M $7.50 Jun 10, 2024 Fairmount Healthcare Fund II LP
Dianthus Therapeutics, Inc. /DE/ Director Common Stock 2.7M $32.4M $12.00 Sep 27, 2024 By Fairmount Healthcare Fund II L.P.
Zenas BioPharma, Inc. Director Common Stock 1.89M $32.2M $17.00 Sep 16, 2024 By Fairmount Healthcare Fund II LP
Oruka Therapeutics, Inc. Director, 10%+ Owner Common Stock 639K $14.7M $23.00 Sep 11, 2024 By Fairmount Healthcare Fund II L.P.
Dianthus Therapeutics, Inc. /DE/ Director Pre-Funded Warrants (Right to Buy) 832K $9.99M $12.00 Jan 22, 2024 Indirect
Oruka Therapeutics, Inc. Director, 10%+ Owner Series A Non-Voting Convertible Preferred Stock 160 $3.68M $23,000.00 Sep 11, 2024 By Fairmount Healthcare Fund II L.P.
Spyre Therapeutics, Inc. Director Common Stock 4.02M $2.85M $0.71 Apr 25, 2024 By Fairmount Healthcare Fund II L.P.
Apogee Therapeutics, Inc. Director Common Stock 51.2K $1.91M $37.26 Mar 28, 2024 By Peter Harwin
Apogee Therapeutics, Inc. Director Common Stock 51.2K $1.91M $37.26 Mar 28, 2024 By Tomas Kiselak
Spyre Therapeutics, Inc. Director Common Stock 406K $288K $0.71 Apr 25, 2024 By Peter Harwin
Spyre Therapeutics, Inc. Director Common Stock 406K $288K $0.71 Apr 25, 2024 By Tomas Kiselak
Dianthus Therapeutics, Inc. /DE/ Director Common Stock 0 $0 $12.00 Sep 27, 2024 By Fairmount SPV III, LLC
Apogee Therapeutics, Inc. Director Non-Voting Common Stock 6.74M Mar 28, 2024 By Fairmount Healthcare Fund II LP
Spyre Therapeutics, Inc. Director Series A Preferred Stock 346K Apr 25, 2024 By Fairmount Healthcare Fund II L.P.
Viridian Therapeutics, Inc.\DE Director, 10%+ Owner Series A Non-Voting Convertible Preferred Stock 133K Mar 28, 2024 By Fairmount Healthcare Fund II LP
Cogent Biosciences, Inc. Director Series A Convertible Preferred Stock 67.4K Mar 28, 2024 Fairmount Healthcare Fund II LP
Viridian Therapeutics, Inc.\DE Director, 10%+ Owner Series B Non-Voting Convertible Preferred Stock 48.5K Oct 30, 2023 By Fairmount Healthcare Fund II LP
Zenas BioPharma, Inc. Director Stock Option (Right to Buy) 37K Sep 12, 2024 By Tomas Kiselak
Spyre Therapeutics, Inc. Director Series B Preferred Stock 16.7K Dec 29, 2023 By Fairmount Healthcare Fund II L.P.
Spyre Therapeutics, Inc. Director Stock Option (Right to Buy) 11.3K May 14, 2024 By Peter Harwin
Spyre Therapeutics, Inc. Director Stock Option (Right to Buy) 11.3K May 14, 2024 By Tomas Kiselak
Dianthus Therapeutics, Inc. /DE/ Director Stock Option (Right to Buy) 11K May 23, 2024 Indirect
Apogee Therapeutics, Inc. Director Stock Option (Right to Buy) 10.4K Jun 5, 2024 Direct
Apogee Therapeutics, Inc. Director Common Stock 0 Mar 28, 2024 By Fairmount Healthcare Fund LP
Apogee Therapeutics, Inc. Director Non-Voting Common Stock 0 Mar 28, 2024 By Fairmount Healthcare Fund LP
Cogent Biosciences, Inc. Director Series A Convertible Preferred Stock 0 Mar 28, 2024 Fairmount Healthcare Fund LP
Cogent Biosciences, Inc. Director Series B Convertible Preferred Stock 0 Jun 10, 2024 Fairmount Healthcare Fund II LP
Viridian Therapeutics, Inc.\DE Director, 10%+ Owner Series A Non-Voting Convertible Preferred Stock 0 Mar 28, 2024 By Fairmount Healthcare Fund LP
Zenas BioPharma, Inc. Director Series A Convertible Preferred Stock 0 Sep 16, 2024 By Fairmount Healthcare Fund II LP
Zenas BioPharma, Inc. Director Series B Convertible Preferred Stock 0 Sep 16, 2024 By Fairmount Healthcare Fund II LP
Zenas BioPharma, Inc. Director Series C Convertible Preferred Stock 0 Sep 16, 2024 By Fairmount Healthcare Fund II LP
Zenas BioPharma, Inc. Director Series Seed Convertible Preferred Stock 0 Sep 16, 2024 By Fairmount Healthcare Fund II LP

Insider Reports Filed by Fairmount Funds Management LLC

Symbol Company Period Transactions Value $ Form Type Date Filed Role
DNTH Dianthus Therapeutics, Inc. /DE/ Sep 27, 2024 1 $0 4 Oct 1, 2024 Director
VRDN Viridian Therapeutics, Inc.\DE Sep 13, 2024 1 $30M 4 Sep 17, 2024 Director, 10%+ Owner
ZBIO Zenas BioPharma, Inc. Sep 12, 2024 10 $5.1M 4/A Sep 17, 2024 Director
ZBIO Zenas BioPharma, Inc. Sep 12, 2024 0 $0 3 Sep 12, 2024 Director, 10%+ Owner
ORKA Oruka Therapeutics, Inc. Sep 11, 2024 2 $10M 4 Sep 13, 2024 Director, 10%+ Owner
ORKA Oruka Therapeutics, Inc. Aug 29, 2024 0 $0 3 Sep 6, 2024 Director, 10%+ Owner
COGT Cogent Biosciences, Inc. Jun 10, 2024 2 $0 4 Jun 12, 2024 Director
APGE Apogee Therapeutics, Inc. Jun 5, 2024 2 $0 4 Jun 7, 2024 Director
DNTH Dianthus Therapeutics, Inc. /DE/ May 23, 2024 1 $0 4 May 28, 2024 Director
SYRE Spyre Therapeutics, Inc. May 14, 2024 2 $0 4 May 16, 2024 Director
SYRE Spyre Therapeutics, Inc. Apr 25, 2024 2 $0 4 Apr 25, 2024 Director
DNTH Dianthus Therapeutics, Inc. /DE/ Apr 1, 2024 2 $0 4 Apr 1, 2024 Director
VRDN Viridian Therapeutics, Inc.\DE Mar 28, 2024 4 $0 4 Apr 1, 2024 Director, 10%+ Owner
COGT Cogent Biosciences, Inc. Mar 28, 2024 4 $0 4 Apr 1, 2024 Director
APGE Apogee Therapeutics, Inc. Mar 28, 2024 4 $0 4 Apr 1, 2024 Director
COGT Cogent Biosciences, Inc. Feb 16, 2024 2 $20M 4 Feb 16, 2024 10%+ Owner
APGE Apogee Therapeutics, Inc. Jan 29, 2024 3 $0 4 Jan 31, 2024 Director
DNTH Dianthus Therapeutics, Inc. /DE/ Jan 22, 2024 2 $20M 4 Jan 24, 2024 Director, 10%+ Owner
VRDN Viridian Therapeutics, Inc.\DE Jan 22, 2024 1 $10M 4 Jan 24, 2024 Director, Other*, 10%+ Owner
SYRE Spyre Therapeutics, Inc. Dec 29, 2023 3 $0 4 Dec 29, 2023 Director, 10%+ Owner
SYRE Spyre Therapeutics, Inc. Dec 7, 2023 1 $10M 4 Dec 11, 2023 Director, 10%+ Owner
AGLE Spyre Therapeutics, Inc. Nov 24, 2023 2 $0 4 Nov 28, 2023 Director, 10%+ Owner
VRDN Viridian Therapeutics, Inc.\DE Oct 30, 2023 1 $40M 4 Nov 1, 2023 Director, Other*, 10%+ Owner
DNTH Dianthus Therapeutics, Inc. /DE/ Sep 29, 2023 1 $336K 4 Oct 3, 2023 Director, 10%+ Owner
DNTH Dianthus Therapeutics, Inc. /DE/ Sep 26, 2023 1 $395K 4 Sep 28, 2023 Director, 10%+ Owner
MGTA Dianthus Therapeutics, Inc. /DE/ Sep 19, 2023 1 $396K 4 Sep 21, 2023 Director, 10%+ Owner
MGTA Dianthus Therapeutics, Inc. /DE/ Sep 11, 2023 3 $272K 4 Sep 13, 2023 Director, 10%+ Owner
MGTA Dianthus Therapeutics, Inc. /DE/ Sep 11, 2023 0 $0 3 Sep 13, 2023 Director, 10%+ Owner
APGE Apogee Therapeutics, Inc. Jul 13, 2023 5 $50M 4 Jul 17, 2023 Director
APGE Apogee Therapeutics, Inc. Jul 13, 2023 0 $0 3 Jul 13, 2023 Director
AGLE Aeglea BioTherapeutics, Inc. Jun 22, 2023 0 $0 3 Jun 30, 2023 Director, 10%+ Owner
COGT Cogent Biosciences, Inc. Jun 9, 2023 1 $9.6M 4 Jun 13, 2023 Other*, 10%+ Owner
VRDN Viridian Therapeutics, Inc.\DE Aug 17, 2022 1 $10M 4 Aug 19, 2022 Director, Other*, 10%+ Owner
COGT Cogent Biosciences, Inc. Jun 16, 2022 1 $9.9M 4 Jun 21, 2022 Other*, 10%+ Owner
VRDN Viridian Therapeutics, Inc.\DE Sep 21, 2021 1 $10M 4 Sep 23, 2021 Director, 10%+ Owner